Ciplas COVID-19 Drug Cipremi To Cost Less Than Rs 5,000 Per Vial

Supported by

Indian drugmaker Cipla Ltd will price ‘Cipremi’, the generic version of US-based Gilead Science Inc’s antiviral drug Remdesivir for COVID-19 patients at less than ₹5,000 ($66) per 100mg vial.

Gilead Science Inc extended a voluntary non-exclusive license to Cipla to manufacture and market the company’s Cipremi.

The company, on Tuesday, June 23 announced that keeping in consideration factors such as accessibility and affordability, it would make the drug available in India in the next eight-ten days at the capped price.

‘In line with our overall philosophy of driving access and affordability, the drug will be priced at less than ₹5,000 per vial for 100 mg injection — among the lowest pricing for Remdesivir globally,’ announced Cipla.

‘We have started commercial manufacturing and the product will be available in the next 8-10 days,’ it added.

According to reports, the drug will be supplied through government and open market channels in a bid to facilitate equitable distribution and mass-accessibility.

‘Cipremi’, a drug for COVID-19 infection, can be used for the treatment of adults and paediatric patients who have been hospitalised. The newly launched drug is considered to be more effective for those who are on oxygen support after being diagnosed with the novel coronavirus.

Cipla and another privately held Indian drugmaker Hyderabad’s Hetero Labs, which also gained approval to sell a generic version of remdesivir in India, had said it expects to price a similar dose of the treatment at ₹5,000-₹6,000.

Also Read: Coronil Got Approval As Immunity Booster, Patanjali Sold It As COVID-19 Cure

#PoweredByYou We bring you news and stories that are worth your attention! Stories that are relevant, reliable, contextual and unbiased. If you read us, watch us, and like what we do, then show us some love! Good journalism is expensive to produce and we have come this far only with your support. Keep encouraging independent media organisations and independent journalists. We always want to remain answerable to you and not to anyone else.

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Amplified by

P&G Shiksha

P&G Shiksha Turns 20 And These Stories Say It All

Amplified by

Isha Foundation

Sadhguru’s Meditation App ‘Miracle of Mind’ Hits 1 Million Downloads in 15 Hours, Surpassing ChatGPT’s Early Growth

Recent Stories

Uttar Pradesh Shocker: Woman Allegedly Kills Mother-in-Law Over Land Dispute, Affairs with Husband’s Brothers

Bengaluru

Bengaluru: Infosys Employee Arrested for Secretly Filming Women Colleagues in Restroom; Over 30 Explicit Videos Found on Phone

JAC Class 11 Results 2025 Declared: 98.7% Pass, Girls Lead as 3.4 Lakh Promoted; Here’s How to Check Your Scores Online

Contributors

Writer : 
Editor : 
Creatives :